期刊文献+

36例隆突性皮肤纤维肉瘤临床诊疗分析 被引量:15

Clinical analysis and treatment for 36 patients with dermatofibrosarcoma protuberans
下载PDF
导出
摘要 目的:分析隆突性皮肤纤维肉瘤误诊率、复发率高的原因,探讨提高治愈率的策略。方法:回顾性分析36例隆突性皮肤纤维肉瘤患者的临床和病理资料。全组病例均行肿瘤局部扩大切除术,切缘距离肿瘤缘2.5~3.0cm,术中快速冷冻切片病理检查至边缘和基底阴性。创面行皮片或皮瓣移植修复,3例多次复发患者手术切除同时行125I放射性粒子组织间植入治疗。结果:临床首诊误诊率高达63.8%(23/36)。36例扩大切除后创面一期愈合率95%。中位随访时间3.4(1~6)年,共4例(11.1%)复发,3例辅以125I粒子植入治疗者,随访1~2年均未复发。全组病例未发现远处转移和死亡。结论:隆突性皮肤纤维肉瘤临床症状不典型是误诊率高的主要原因,病理检查是明确诊断的方法,手术扩大切除是提高治愈率的关键,放射性粒子组织间近距离治疗是较好的辅助疗法。 Objective:To study the reasons of misdiagnosis and postoperative recurrence of derrnatofibrosarcoma protuberan(DFSP) and find out effective ways to improve its cure rate. Methods:The clinical and pathological data of 36 patients with DFSP was submitted to a retrospective study. All 36 patients underwent wide excisions with intraoperative frozen sections. The surgical margins were between 2.5 and 3.0 era. Three patients with relapse history were treated with ^125I radioactive seeds implantation. Results:The clinical misdiagnosis rate at first diagnosis was high to 63.8%(23/36). The operative wounds of all 36 extensive resections were covered with skin grafts or flap transplantations,and the primary healing rate was 95%. The median follow-up period was 3.4 (1-6)years and 4 (11.1%)cases recurred. Three patients with ^125I radioactive seeds implantation were followed up for 1 year to 2 years and none of them had recurrence. There were neither distant metastasis nor death in all cases. Conclusion:The high misdiagnosis rate of DFSP is mainly attributed to untypical early symptoms. The diagnosis of DFSP depends on pathological examination. Wide excision is the crucial measure to improve cure rate and interstitial brachytherapy is an effective adjunctive therapy.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2009年第8期1181-1184,共4页 Journal of Nanjing Medical University(Natural Sciences)
基金 南京医科大学科技创新基金项目(CX2002008)
关键词 隆突性皮肤纤维肉瘤 扩大切除 近距离放射治疗 dermatofibrosarcoma protuberans wide excision brachytherapy
  • 相关文献

参考文献15

  • 1Grant McArthur. Dermatofibrosarcoma protuberans: Recent Clinical Progress [J]. Annals of Surgical Oncology, 2007,14(10) :2876-2886.
  • 2Mori T,Misago N,Yamamoto O,et al. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma[J]. J Dermatol,2008,35(7) :419-425.
  • 3Mentzel T,Scharer L,Kazakov DV,et al. Myxoid dermatofibrosarcoma protuberans : clinicopathologic, immunohistochemical,and molecular analysis of eight cases [J]. Am J Dermatopathol, 2007,29 (5) : 443-448.
  • 4Sanmartin O,Llombart B,Lopez-Guererro JA,et al. Dermatofibrosarcoma Protuberans [J]. Actas Dermosifiliogr, 2007,98 (2) : 77-87.
  • 5Sondak VK,Cimmino VM,Lowe LM,et al. Dermatofibrosarcoma protuberans:what is the best surgical approach[J]. Surg Oncol, 1999,8(2): 183-189.
  • 6Vincent T, De Vita,Steven A. Cancer-Principles & Practice of Oncology[M]. 5版.山东:山东科学技术出版社,2001:1814.
  • 7Yu W,Tsoukas MM,Chapman SM,et al. Surgical treatment for dermatofibrosarcoma protuberans:the Dartmouth experience and literature review [J]. Ann Plast Surg. 2008,60(3 ) : 288-293.
  • 8Kimmel Z,Ratner D,Kim JY,et al. Peripheral excision margins for dermatofibrosarcoma protuberans:a meta- analysis of spatial data [J]. Ann Surg 0ncol,2007,14 (7) :2113-2120.
  • 9Paradisi A,Abeni D,Rusciani A,et al. Dermatofibrosarcoma protuberans:wide local excision vs. Mohs micrographic surgery[J]. Cancer Treat Rev,2008,34(8) :728-736.
  • 10Ratner D,Thomas CO,Johnson TM,et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans Results of a multi institutional series with an analysis of the extent of microscopic spread[J]. J Am Acad Dermatol, 1997,37(4) :600-613.

二级参考文献16

  • 1徐建明,宋三泰.表皮生长因子受体酪氨酸激酶靶向药物与化疗联合应用的合理设计[J].中华肿瘤杂志,2004,26(6):321-323. 被引量:20
  • 2李力军,高宏,封国生,刘璐,童冠圣,单毅,吕大鹏,杜伟生.放射性粒子^(125)I与缓释化疗粒子联合应用靶向治疗复发性直肠癌[J].中国实用外科杂志,2004,24(10):612-613. 被引量:18
  • 3Mark RJ,Bailet JW,Tran LM,et al.Dermatofibrosarcomaprotuberans of the head and neck:a report of 16 cases[J].Arch Otolaryngol Head Neck Surg,1993,119(8):891-896.
  • 4Suit H,Spiro I,Mankin HJ,et al.Radiation in management of patients with dermatofibrosarcoma protuberans[J].J Clin Oncol,1996,14(8):2365-2369.
  • 5Rutgers EJ,Kroon BB,Albus-Lutter CE,et al.Dermatofibrosarcoma protuberans:treatment and prognosis[J].Eur J Surg Oncol,1992,18(3):241-248.
  • 6Gayner SM,Lewis JE,McCaffrey TV.Effect of resection margins on dermatofibrosarcoma protuberans of the head and neck[J].Arch Otolaryngol Head Neck Surg,1997,123(4):430-433.
  • 7Rubin BP,Schuetze SM,Eary JF,et al.Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans[J].J Clin Oncol,2002,20(17):3586-3591.
  • 8Pedeutour F,Coindre JM,Nicolo G,et al.Ring chromosomes in dermatofibrosarcoma protuberans contain chromosome 17 sequences:fluorescence in situ hybridization[J].Cancer Genet Cytogenet,1993,67(2):149.
  • 9Naeem R,Lux ML,Huang SF,et al.Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22[J].Am J Pathol,1995,147(6):1553-1558.
  • 10Buchdunger E,Cioffi CL,Law N,et al.Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors[J].J Pharmacol Exp Ther,2000,295(1):139-145.

共引文献6

同被引文献89

引证文献15

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部